Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting
Status:
NOT_YET_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, active-controlled dose-finding study. About 180 subjects who receive a high emetic chemotherapy are planned to be enrolled and randomized into three groups by a ratio of 1:1:1.
Phase:
PHASE2
Details
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University